fk 156 has been researched along with aclarubicin in 1 studies
| Studies (fk 156) | Trials (fk 156) | Recent Studies (post-2010) (fk 156) | Studies (aclarubicin) | Trials (aclarubicin) | Recent Studies (post-2010) (aclarubicin) |
|---|---|---|---|---|---|
| 28 | 0 | 4 | 826 | 97 | 105 |
| Protein | Taxonomy | fk 156 (IC50) | aclarubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 9.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, K; Turk, JL | 1 |
1 other study(ies) available for fk 156 and aclarubicin
| Article | Year |
|---|---|
Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.
Topics: Aclarubicin; Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzodiazepinones; Diaminopimelic Acid; Dose-Response Relationship, Immunologic; Interleukin-1; Interleukin-2; Male; Oligopeptides; Rats; Rats, Inbred Lew; Spleen | 1989 |